ReviewInflammopharmacology2025
Curcumin: multifaceted biological actions and therapeutic implications-a narrative review.
Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Curcumin and Cancer Stem Cells: Epigenetic Mechanisms Underlying Therapeutic Resistance and Tumor Relapse.International journal of molecular sciences · 2026Review
- Integrated bulk and single-cell transcriptomic analyses and experimental validation reveal the pathogenic role of chondrocyte pyroptosis in osteoarthritis and the therapeutic potential of curcumin via its targeted modulation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Curcumin's Protective Effects Against HMolecules (Basel, Switzerland) · 2026Review
- Curcumin Between Pleiotropic Potential and Translational Constraints.International journal of molecular sciences · 2026Review
- Anti-Leukemic Properties of Curcumin on Acute Lymphoblastic Leukemia: A Systematic Review.Biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Curcumin, a bioactive polyphenol extracted from the rhizome of Curcuma longa, has garnered considerable attention for its wide-ranging pharmacological properties and potential therapeutic applications. This narrative review critically synthesizes current evidence on curcumin's multifaceted biological actions, encompassing its antioxidant, anti-inflammatory, anti-cancer, and metabolic regulatory effects. Extensive preclinical and clinical studies have demonstrated that curcumin exerts beneficial effects by modulating key cellular signaling pathways and mitigating oxidative stress and inflammatory responses. Despite its promising profile, clinical translation has been hampered by issues related to low bioavailability and rapid metabolism. Recent advances in novel formulation strategies and combination therapies, however, have shown potential in overcoming these limitations. This review uniquely consolidates recent mechanistic insights with clinical translation challenges, identifying specific gaps in bioavailability research and proposing novel combination therapy approaches that distinguish it from existing curcumin reviews, ultimately facilitating evidence-based therapeutic development.
Indexed as
Identifiers
41045344What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.